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Summary
Endocrine resistance leads to recurrence and death from breast cancer. Animal models of endocrine resistance enable preclinical identification of efficacious therapeutic combinations and further our understanding of resistance. This strategy provides new insights into optimally targeting interactions between estrogen receptor (ESR-1) activity and the cell cycle by CDK4/6 inhibitors.
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Author Manuscript Published OnlineFirst on July 22, 2015; DOI: 10.1158/1078-0432. CCR-15-1146 In this issue of Clinical Cancer Research, Wardell and colleagues utilized mouse models of endocrine therapy-resistant breast cancer to probe the relative efficacy of the cyclin-dependent kinase (CDK) 4/6 inhibitor, palbociclib, emerging endocrine agents, and their combination (1) . Estrogen receptor (ER)-expressing breast cancer is the most common form of the disease, comprising nearly 80% of the more than 200,000 new cases diagnosed annually. While highly treatable by therapies that block ER signaling or prevent the production of its ligand, estrogen, resistance to endocrine therapy is universal in the metastatic setting and is also thought to be a common mechanism of recurrence in early-stage disease. The frequent occurrence of therapeutic resistance, coupled with the unparalleled high prevalence of this malignancy, mandates new approaches to overcoming endocrine resistance if continued improvements in survival are to be achieved.
Current therapies targeting ER function include depletion of endogenous estrogens through aromatase-inhibition (AIs), as well as blockade of estrogen binding to ER by selective estrogen receptor modulators (SERMS) and/or degraders (SERDS). While these approaches are highly effective for some cancers, alterations resulting in estrogen-independent nuclear signaling or activation of escape pathways engender resistance. For example, activating mutations in ESR1 can render ER signaling ligandindependent (2). Similarly, changes in ER coactivators and corepressors can enable growth of ER+ cells despite low levels of estrogen.
Alternative resistance mechanisms involve ER-driven activation of oncogenic signaling pathways, including the PI3K/Akt/mTOR pathway (3), and interactions with the In tamoxifen-resistant xenograft models, palbociclib increased the efficacy with which SSHs inhibited tumor growth/proliferation. Each of the SSHs/SERDs efficiently down-regulated ESR1, inhibited ESR1 transcriptional activity, and inhibited tumor growth. Surprisingly, palbociclib alone in these models induced regression followed by rapid resistance, without loss of RB. While palbociclib had no effect on ESR1 expression or activity, the combination of BZA and palbociclib -but not the combination of palbociclib with ICI or PIP -significantly extended the duration or response compared to either treatment alone. In the PDX model, BZA and palbociclib had similar inhibitory effects on growth, both in the presence and absence of the ESR1-Y5375 mutant, and in For these reasons and others, it is highly likely that overcoming endocrine resistance will require understanding the complex cellular dynamics of tumor evolution and the ability to target multiple alternate escape pathways simultaneously or sequentially. Ultimately, it is unclear whether approaches to preventing the emergence of endocrine resistance in the setting of metastatic disease will be applicable to escape from endocrine therapy in the setting of micrometastatic minimal residual disease, particularly to the extent that this may involve a dormant state of cellular quiescence.
Animal models hold great promise both to further our understanding of the biology of endocrine resistance and to speed the discovery of improved therapeutic approaches.
Further development of these models and genomic assessment of the cellular effects of therapy are of paramount importance to informing translational human trials.
